Search results
Showing 61 to 75 of 280 results for coronavirus
This quality standard covers the initial assessment and management of suspected acute respiratory infection in over 16s, including acute respiratory infection virtual wards.
View quality statements for QS210Show all sections
Sections for QS210
- Quality statements
- Quality statement 1: Documented initial assessment
- Quality statement 2: Prescribing antimicrobials
- Quality statement 3: Antibiotic duration
- Quality statement 4: Information about acute respiratory infection virtual wards
- Quality statement 5: Multidisciplinary team
- Quality statement 6: Support to self-manage on a virtual ward
- Quality statement 7: Virtual ward discharge summaries
standard care or conventional oxygen therapy for people in hospital with COVID-19 and respiratory failure when it is agreed...
NG188/2 Question What is the prevalence and incidence of post-COVID-19 syndrome in patients who have received single,...
and safety of the combination of casirivimab and imdevimab for treating COVID-19 in people with particular clinical...
This guideline covers interventions to prevent sexually transmitted infections (STIs) in people aged 16 and over. It aims to reduce the transmission of all STIs, including HIV, and includes ways to help increase the uptake of STI testing and vaccines for human papillomavirus (HPV) and hepatitis A and B.
Browse the complete list of all our published health and social care guidance, including guidelines, NICE advice and quality standards
tools (including physical, psychological and psychiatric aspects) for post-COVID-19 syndrome in a UK population. What tools...
This evidence summary was produced at the start of the COVID-19 pandemic, when evidence was emerging. It has been withdrawn as the content is no longer relevant. See NICE's COVID-19 rapid guideline: managing COVID-19 for current guidance.
COVID-19 rapid evidence summary: Tocilizumab for COVID-19 (ES33)
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
COVID-19 rapid evidence summary: Sarilumab for COVID-19 (ES34)
This guideline has been updated and replaced by NICE COVID-19 rapid guideline NG191.
Social, emotional and mental wellbeing in primary and secondary education (NG223)
This guideline covers ways to support social, emotional and mental wellbeing in children and young people in primary and secondary education (key stages 1 to 5), and people 25 years and under with special educational needs or disability in further education colleges. It aims to promote good social, emotional and psychological health to protect children and young people against behavioural and health problems.
FebriDx for C-reactive protein and myxovirus resistance protein A testing (MIB224)
NICE has developed a medtech innovation briefing (MIB) on FebriDx for C-reactive protein and myxovirus resistance protein A testing .
Behaviour change: digital and mobile health interventions (NG183)
This guideline covers interventions that use a digital or mobile platform to help people eat more healthily, become more active, stop smoking, reduce their alcohol intake or practise safer sex. The interventions include those delivered by text message, apps, wearable devices or the internet. The guideline only includes those that are delivered by the technology itself and not by healthcare professionals using technology to deliver interventions.
In development Reference number: GID-TA11352 Expected publication date: TBC